SynthesisJournal of global health2026
Proteome-wide Mendelian randomisation identifies causal links between blood proteins and myopia.
Synthesis in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myopia is one of the most prevalent eye diseases worldwide, and its incidence is increasing. However, effective pharmaceutical treatments remain limited. We aimed to identify blood proteins causally associated with myopia as potential drug targets. Methods: We performed a genome-wide association study (GWAS) meta-analysis involving 43 862 myopia cases and 84 820 controls. Then, we conducted a Mendelian randomisation (MR) analysis of blood proteins by utilising the deCODE and UK Biobank Pharma Proteomics Project datasets, and validated the correlations between these characteristics through a cross-sectional study of 50 586 individuals, including 3108 with myopia. Subsequently, through protein-protein interaction (PPI) analyses, we explored potential connections between proteins and existing myopia treatments. Results: The GWAS meta-analysis found 26 genetic risk loci for myopia, including nine novel loci. The cross-sectional study showed correlations between height, smoking, and myopia. Proteome-wide MR analysis identified 164 plasma proteins potentially causally linked to myopia, with 20 proteins validated in both datasets. Genetic colocalisation analysis, PPI, and drug target analyses identified promising therapeutic targets for myopia. Conclusions: We identified genetic loci associated with myopia and proteins with potential causal roles in its development. These results indicate new genetic architectures underlying myopia, offering potential treatment targets and a foundation for personalised therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.